wmm, Author at Invivoscribe

About wmm

This author has not yet filled in any details.
So far wmm has created 24 blog entries.

Invivoscribe To Present At Biotech Showcase™ 2019 In San Francisco

wmm2019-07-04T21:02:41+00:00January 3rd, 2019|Categories: Press Releases|Tags: CDx, Companion Diagnostics, Dr. Jeffrey E. Miller Ph.D., EMA, FDA, PMDA, Streamlined CDx|

⟵ PRESS RELEASES PRESS RELEASE SAN FRANCISCO, [...]

Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Software

wmm2019-07-04T21:12:43+00:00November 7th, 2017|Categories: Press Releases|Tags: LymphoTrack, LymphoTrack® TRB Assay, Minimal Residual Disease, MiSeq®, MRD, MRD Software|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.

wmm2019-07-04T21:14:04+00:00August 1st, 2017|Categories: Press Releases|Tags: CDx, CE-Marked, CE-marked IVD Assay, FLT3, LeukoStrat, LeukoStrat® CDx FLT3 Mutation Assay|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

FDA approves new combination treatment for acute myeloid leukemia

wmm2019-07-04T21:14:53+00:00April 28th, 2017|Categories: Press Releases|Tags: Acute Myeloid Leukemia, AML, Combination Treatment, FDA, FDA Approval|

⟵ PRESS RELEASES PRESS RELEASE SILVER SPRING, [...]

Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AML

wmm2019-07-04T21:16:10+00:00April 28th, 2017|Categories: Press Releases|Tags: Acute Myeloid Leukemia, AML, CDx, Companion Diagnostics, FDA, FDA Approval, LeukoStrat, LeukoStrat® CDx FLT3 Mutation Assay, Rydapt®|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapies

wmm2019-07-04T21:17:23+00:00March 28th, 2017|Categories: Press Releases|Tags: Assays, CAR-T, CAR-T and TCR Immuno-Therapies, Immuno-Therapies, Services, Solid Tumors, TCR|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Software

wmm2019-07-04T21:19:54+00:00February 28th, 2017|Categories: Press Releases|Tags: Bioinformatics, Bioinformatics Software, CE-IVD, CE-IVD Clonality Kits, Clonality, Ion PGM, Ion PGM NGS Platform Menu, Minimal Residual Disease, MRD, MRD Software, Next-Generation Sequencing, NGS, Research Use Only, RUO|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kits

wmm2019-07-04T21:21:15+00:00February 14th, 2017|Categories: Press Releases|Tags: Illumina, IVD, IVD Assay Kits, Next-Generation Sequencing, NGS|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits

wmm2019-07-04T21:25:15+00:00January 31st, 2017|Categories: Press Releases|Tags: Clonality, Clonality Assay Kits, FLT3, FLT3 Mutations, Internal Tandem Duplication, ITD, Next-Generation Sequencing, NGS, NGS Based Assays, TKD, Tyrosine Kinase Domain|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis

wmm2019-07-04T21:27:37+00:00November 14th, 2016|Categories: Press Releases|Tags: Acute Myeloid Leukemia, Advanced Systemic Mastocytosis, AML, FDA, FDA Priority Review, FLT3, FLT3-mutated AML, Midostaurin, Novartis, Novartis drug PKC412|

⟵ PRESS RELEASES PRESS RELEASE Basel - [...]

Load More Posts

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS COVID-19 TESTING

Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate
drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

August 13th, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

October 30th, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

August 13th, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

About wmm

Invivoscribe To Present At Biotech Showcase™ 2019 In San Francisco

Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Software

Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.

FDA approves new combination treatment for acute myeloid leukemia

Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AML

Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapies

Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Software

Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kits

Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits

Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS COVID-19 TESTING Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

Browse our comprehensive menu of product & testing services.

A proven strategy to acceleratedrug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

August 13th, 2020 Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

October 30th, 2020 Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

August 13th, 2020 Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

About wmm

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS COVID-19 TESTING

Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

A proven strategy to accelerate
drug approvals

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

August 13th, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

October 30th, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

August 13th, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia